Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P. Curr Med Chem. 2011, 18(18), p2686-714.

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.

Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases. Shuttleworth S, Townsend P, Silva F, Cecil A, Hill T, Tomassi C, Rogers H, Harrison R. Prog Med Chem. 2011, 50, p109-33.